1448334-90-4

Basic information

• Product Name: 1-(2,5-dichloro-thiophene-3-sulfonyl)-4-[5-(4-methoxyphenyl)-[1,3,4]oxadiazol-2-yl]piperazine
• Synonyms: 1-(2,5-dichloro-thiophene-3-sulfonyl)-4-[5-(4-methoxyphenyl)-[1,3,4]oxadiazol-2-yl]piperazine
• CAS NO: 1448334-90-4
• Molecular Weight: 475.376
• Mol File: 1448334-90-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(2,5-dichloro-thiophene-3-sulfonyl)-4-[5-(4-methoxyphenyl)-[1,3,4]oxadiazol-2-yl]piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,5-dichloro-thiophene-3-sulfonyl)-4-[5-(4-methoxyphenyl)-[1,3,4]oxadiazol-2-yl]piperazine(1448334-90-4)
• EPA Substance Registry System: 1-(2,5-dichloro-thiophene-3-sulfonyl)-4-[5-(4-methoxyphenyl)-[1,3,4]oxadiazol-2-yl]piperazine(1448334-90-4)

Safety Data

• Hazardous Substances Data: 1448334-90-4(Hazardous Substances Data)

Upstream product

• 1448334-83-5 tert-butyl-4-[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]piperazine-1-carboxylate 
• 1368483-63-9 2-bromo-5-(4-methoxyphenyl)-1,3,4-oxadiazole 
• 829-35-6 2-(4-methoxyphenyl)-1,3,4-oxadiazole 
• 100-09-4 4-methoxybenzoic acid 
• 3290-99-1 4-methoxybenzoic acid hydrazide 
• 56946-83-9 2,5-dichlorothiophene-3-sulfonyl chloride 
• 94-30-4 ethyl 4-methoxybenzoate 

Relevant articles and documents

Synthesis of novel 1-[5-(4-methoxy-phenyl)-[1,3,4]oxadiazol-2-yl]- piperazine derivatives and evaluation of their in vivo anticonvulsant activity

A series of novel 1-[5-(4-methoxy-phenyl)-[1,3,4]oxadiazol-2-yl]-piperazine derivatives 8(a-o) were synthesized and characterized by elemental analyses, 1H NMR, 13C NMR and mass spectral studies. The newly synthesized compounds were screened for their anticonvulsant activity against maximal electroshock seizure (MES) model in male wistar rats and compared with the standard drug phenytoin. The neurotoxic effects were determined by rotorod test by using mice. Compounds 8d, 8e, 8f and 8h were found to be most potent of this series. The same compounds showed no neurotoxicity at the maximum dose administered (100 mg/kg). The efforts were also made to establish the structure activity relationships among synthesized compounds. The pharmacophore model was used to validate the anticonvulsant activity of the synthesized molecules.